Aerie Pharma (AERI) Misses Q4 EPS by 44c

Aerie Pharma (NASDAQ: AERI) reported Q4 EPS of ($1.21), $0.44 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $24.66 million versus the consensus estimate of $19.46 million.

2020 Guidance

Aerie currently expects full-year 2020 net revenues to be in the range of $100 to $110 million on a U.S. GAAP basis for Rhopressa® and Rocklatan® combined. Aerie also currently expects full-year 2020 net cash used in operating activities to be in the range of $110 million to $120 million, on a U.S. GAAP basis, with operating expenses in full-year 2020 remaining consistent with full-year 2019.

For earnings history and earnings-related data on Aerie Pharma (AERI) click here.

You May Also Be Interested In

• Grainger (GWW) Tops Q1 EPS by 2c, provides guidance
• United Bankshares (UBSI) Misses Q1 EPS by 1c
• Union Pacific (UNP) Tops Q1 EPS by 18c